PriMera Scientific Surgical
Research and Practice
Volume 8 Issue 2 August 2026
DOI: 10.56831/PSSRP-08-314
ISSN: 2836-0028

PriMera Scientific Publications

# Multiple Sclerosis and Integrative Innovative Approaches in Science

**Type:** Review Article
**Received:** June 22, 2026
**Published:** August 04, 2026

**Citation:**
Christina Rahm. "Multiple Sclerosis and Integrative Innovative Approaches in Science". PriMera Scientific Surgical Research and Practice 8.2 (2026): 172-177.



**Christina Rahm***

*DRC VENTURES LLC, USA*

***Corresponding Author:** Christina Rahm, DRC VENTURES LLC, USA.

## Abstract

Multiple sclerosis (MS) is a chronic, immune-mediated neurological disorder characterized by demyelination, axonal injury, and progressive functional decline. Although disease-modifying therapies reduce relapse rates and radiologic disease activity, many patients continue to experience persistent symptoms such as fatigue, cognitive impairment, pain, and mood disturbances. These limitations highlight that immune suppression alone does not fully address the complexity of MS pathology.

MS involves interconnected mechanisms including neuroinflammation, immune dysregulation, oxidative stress, mitochondrial dysfunction, and early neurodegeneration. The disease is multifactorial, influenced by genetic susceptibility and environmental factors such as vitamin D deficiency and Epstein-Barr virus exposure. Current pharmacologic therapies improve outcomes but are less effective for chronic symptoms, carry potential risks, and show variability in patient response, particularly in progressive disease forms.

Due to these challenges, interest has grown in adjunctive, multi-component interventions targeting inflammatory, metabolic, oxidative, and gut-brain pathways. The reviewed patented protocol proposes six formulations administered alongside standard care, categorized functionally as antioxidant support, anti-inflammatory compounds, micronutrient replenishment, microbiome modulation, metabolic enhancement, bioenergetic support, neurotransmission modulation, and detoxification mechanisms. Proposed components include NAD+ for mitochondrial support, Mucuna pruriens for dopaminergic modulation, and clinoptilolite zeolite for potential detoxification support. While mechanistically plausible and supported by preclinical or associative evidence, optimal dosing and synergistic effects remain insufficiently studied.

Evidence for the protocol currently includes limited case-based observation, which cannot establish efficacy due to methodological limitations. Controlled clinical trials are necessary to evaluate safety, biomarkers, and functional outcomes. Ethical integration requires transparent patient guidance, careful safety consideration, and scientific rigor.

Overall, the proposed nutraceutical framework is presented as hypothesis-generating rather than an established treatment. While biologically plausible, it requires rigorous clinical investigation before conclusions regarding therapeutic benefit or disease modification can be made.

## Multiple Sclerosis

Multiple sclerosis (MS) is a chronic, immune-mediated, demyelinating, axonally injurious, and progressively disabling neurological disorder. Although disease-modifying therapies play a vital role in reducing relapse rates and radiologic disease activity, a significant percentage of patients continue to experience disabling symptoms that interfere with daily functioning and quality of life. Even optimal pharmacologic treatment does not eliminate persistent fatigue, cognitive deficits, pain, and mood disturbances. These ongoing challenges suggest that inflammatory suppression alone is insufficient to address the full spectrum of MS pathology.

As a result, interest has increased in adjunctive interventions that target metabolic, oxidative, and immunological mechanisms in addition to conventional therapies. Integrative practices that include nutritional and lifestyle-based interventions are increasingly discussed within the context of MS care (Grosu et al., 2025). This white paper analyzes a multi-component nutraceutical algorithm based on Patent Docket No: crahm2025-12 and evaluates its scientific feasibility using existing evidence. The purpose is not to determine therapeutic efficacy but to provide information that may guide future research.

## Background and Pathophysiology of Multiple Sclerosis

Multiple sclerosis is a complex disorder characterized by interactions among neuroinflammation, immune dysregulation, and neurodegeneration within the central nervous system. Autoreactive lymphocytes invade the brain and spinal cord, initiating inflammatory cascades that damage myelin sheaths and impair axonal conduction (García-Domínguez, 2025). Over time, repeated inflammatory injury leads to cumulative axonal damage and irreversible neurological impairment.

Additional tissue injury is associated with mitochondrial dysfunction and oxidative stress, particularly in progressive disease phenotypes (Qin et al., 2024). Emerging research indicates that neurodegeneration may occur early in the disease process, even in the absence of active inflammatory lesions. This evolving paradigm challenges earlier models that viewed MS solely as a relapsing inflammatory disorder (Garton et al., 2024).

Clinically, these mechanisms manifest as sensory impairment, motor disability, fatigue, and cognitive decline. The multifactorial nature of MS supports investigation into treatment strategies that extend beyond immune suppression alone.

## Epidemiology and Risk Factors

Multiple sclerosis affects millions worldwide and remains one of the most common causes of non-traumatic neurological disability in young and middle-aged adults. Incidence rates vary geographically, with the highest prevalence reported in North America and Northern Europe. Women are disproportionately affected, suggesting hormonal and immunological influences (Shi et al., 2024).

Although genetic predisposition contributes to disease risk, environmental factors play a substantial role in MS development. Vitamin D deficiency has been associated with increased susceptibility and higher relapse rates (Carlberg & Mycko, 2023). Viral exposures are also significant, with Epstein-Barr virus infection demonstrating a strong temporal association with MS onset (Thomas et al., 2023). Evidence suggests immune priming related to viral latency and dysregulated immune surveillance (Cuppen & Savelkoul, 2025). These findings underscore the multifactorial etiology of MS and support attention to prevention strategies and adjunctive approaches targeting modifiable risk factors.

## Limitations of Current Therapeutic Approaches

Disease-modifying therapies have improved MS outcomes by reducing relapse frequency and delaying disability progression. However, these therapies are less effective in managing chronic symptoms such as fatigue, cognitive dysfunction, and pain (Shirol et al., 2025). Cognitive impairment, in particular, significantly affects occupational and social functioning (Benedict et al., 2020).

Many treatments carry risks, including immunosuppression, infection, and potential long-term organ toxicity, which may limit adherence and patient acceptance. Considerable variability in therapeutic response reflects disease heterogeneity and differences in

immune biology (Nguyen et al., 2025). Progressive forms of MS remain particularly challenging to manage with pharmacologic therapy alone.

These limitations contribute to growing patient interest in complementary interventions aimed at symptom management and functional preservation (Rajabi et al., 2025). While such approaches cannot replace evidence-based therapies, their popularity highlights the need for scientific evaluation and professional guidance.

## Rationale for Multi-Component Adjunctive Interventions

The heterogeneous and multifaceted pathogenesis of MS suggests potential limitations of single-target adjunctive therapies. Inflammatory, oxidative, metabolic, and neurodegenerative pathways interact dynamically throughout the disease course, contributing to symptom complexity (Campagnoli et al., 2024).

Systems-based treatment models aim to address multiple physiological mechanisms simultaneously, potentially achieving broader therapeutic impact (Jason & Bobak, 2022). Nutritional interventions targeting fatigue and inflammatory imbalances have demonstrated potential immunomodulatory effects in MS populations (Stoiloudis et al., 2022). Additionally, low-dose stressor-induced adaptive cellular responses may promote resilience and functional preservation through hormetic mechanisms (Wan et al., 2024).

Multi-component frameworks are clinically relevant, as patients frequently use multiple supplements in practice. Although these approaches present research challenges, they align with personalized medicine paradigms that account for MS heterogeneity (Sadee et al., 2023). This rationale forms the conceptual basis of the proposed adjunctive protocol.

## Conceptual Description of the Adjunctive Protocol

The proposed adjunctive protocol consists of six parallel formulations administered over an extended treatment period. Rather than focusing on proprietary composition, the framework may be categorized functionally into antioxidant support, anti-inflammatory compounds, micronutrient replenishment, gut microbiome modulation, and metabolic enhancement.

A gradual dosage escalation is incorporated to enhance tolerability and minimize adverse effects, consistent with principles in nutritional pharmacokinetics (Barberio et al., 2025). The prolonged treatment duration reflects the chronic nature of MS and the slow pace of neurobiological adaptation.

Importantly, the protocol is designed for use alongside disease-modifying therapies rather than as a replacement for standard care. This conceptual framing allows evaluation of theoretical mechanisms without implying clinical superiority, supporting scientific discussion while maintaining appropriate therapeutic caution.

## Mechanistic Plausibility and Supporting Evidence

Research supports the mechanistic relevance of several components commonly included in integrative MS protocols. Oxidative stress contributes significantly to axonal injury, and antioxidant compounds may mitigate reactive oxygen species–mediated damage (Dash et al., 2024). Curcuminoids have demonstrated inhibition of inflammatory signaling and disease severity reduction in experimental autoimmune encephalomyelitis models (Mavaddabi et al., 2021).

Vitamin D functions as an immunoregulatory hormone, and deficiency has been associated with increased relapse activity and MRI lesion burden (Hajeer et al., 2023). Flavonoids such as quercetin may influence immune cell differentiation and cytokine production relevant to MS-related immune dysfunction (Javanbakht et al., 2023).

Alterations in the gut microbiome have also emerged as a potential avenue for immune modulation in MS (Nemati et al., 2025). While these mechanisms are biologically plausible, optimal dosing strategies and combined effects remain insufficiently studied.

## Expanded Mechanistic Considerations: Bioenergetics, Neurotransmission, and Detoxification

Beyond conventional antioxidants, the protocol includes compounds targeting bioenergetics and neurotransmission. Formulation 6 contains Beta-Nicotinamide Adenine Dinucleotide (NAD+), a critical coenzyme in mitochondrial electron transport and DNA repair. Mitochondrial dysfunction is increasingly recognized as a contributor to neurodegeneration in MS, and NAD+ restoration has demonstrated neuroprotective effects in preclinical models (Yusri et al., 2025).

Formulation 2 includes *Mucuna pruriens*, a natural source of L-DOPA, which influences dopaminergic signaling. Dopamine pathways regulate gait, motivation, and executive function, suggesting a potential mechanism for symptomatic modulation.

Formulation 1 incorporates clinoptilolite zeolite, theorized to support detoxification processes. Zeolites have demonstrated the capacity to bind heavy metals and influence intestinal permeability, potentially reducing systemic inflammatory burden (Zaigham & Paeng, 2024). These mechanisms remain theoretical but are biologically plausible.

## Case-Based Observations and Evidence Limitations

The patented protocol includes a single reported case describing symptom improvement over time. While such observations may generate hypotheses, they do not establish therapeutic efficacy. Single-case designs are inherently susceptible to placebo effects, regression to the mean, and variability in disease activity (Cimino & Braun, 2023).

MS relapse patterns are unpredictable, complicating interpretation of uncontrolled outcomes. Improvements may also be influenced by concurrent pharmacologic therapy or lifestyle modifications. Without standardized outcome measures, control groups, or blinding, causal attribution is not possible.

Distinguishing anecdotal observations from empirical evidence is essential in academic evaluation. These limitations underscore the need for controlled clinical trials before drawing conclusions regarding clinical efficacy or disease modification.

## Ethical, Clinical, and Research Considerations

Adjunctive integrative approaches raise important ethical and clinical considerations in MS care. Patients frequently seek complementary interventions for symptom relief, requiring clinicians to provide evidence-informed guidance. Informed consent necessitates transparent discussion of uncertain benefits and potential risks (Ee et al., 2020).

Safety concerns include product variability, potential drug–nutrient interactions, and financial burden. Methodologically, evaluating multi-component protocols presents challenges related to standardization and attribution of outcomes (Puri et al., 2022).

Appropriate next steps include pilot studies assessing safety, feasibility, and patient-reported outcomes. Ethical integration requires balancing patient autonomy, scientific rigor, and clinical responsibility.

## Conclusion and Future Directions

This white paper reviews a patented multi-component nutraceutical protocol for multiple sclerosis as a theoretical adjunctive approach rather than an established treatment. Available literature supports biological plausibility across inflammatory, oxidative, immune-regulatory, mitochondrial, and gut-brain pathways relevant to MS management.

However, the absence of controlled clinical evidence precludes conclusions regarding efficacy or disease modification. Future research should prioritize rigorously designed trials evaluating safety, biomarkers, and functional outcomes. Such studies are necessary to determine whether integrative adjunctive strategies can meaningfully complement current therapies. Until such data are available, these protocols should be considered hypothesis-generating and implemented cautiously within comprehensive, evidence-based MS care frameworks.

## References

1. Barberio B., et al. "Dietary interventions and oral nutritional supplementation in inflammatory bowel disease: Current evidence and future directions". Nutrients 17.11 (2025): 1879.
2. Benedict RHB., et al. "Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues". The Lancet Neurology 19.10 (2020): 860-871.
3. Campagnoli LIM., et al. "New therapeutic avenues in multiple sclerosis: Is there a place for gut microbiota-based treatments?". Pharmacological Research 209 (2024): 107456.
4. Carlberg C and Mycko MP. "Linking Mechanisms of Vitamin D Signaling with Multiple Sclerosis". Cells 12.19 (2023): 2391.
5. Cimino J and Braun C. "Design a Clinical research Protocol: Influence of Real-World setting". Healthcare 11.16 (2023): 2254.
6. Cuppen JJM and Savelkoul HFJ. "Immune Delay, Beyond Immune Evasion, as a Driver of Pathogen Propagation Competence Through Neutrophil Dysregulation, to be Mitigated by Low-Frequency Electromagnetic Fields (LF-EMF)". International Journal of Molecular Sciences 27.1 (2025): 143.
7. Dash UC., et al. "Oxidative stress and inflammation in the pathogenesis of neurological disorders: Mechanisms and implications". Acta Pharmaceutica Sinica B 15.1 (2025): 15-34.
8. Ee C., et al. "An integrative collaborative care model for people with mental illness and physical comorbidities". International Journal of Mental Health Systems 14.1 (2020): 83.
9. García-Domínguez M. "White Matter in crisis: Oligodendrocytes and the pathophysiology of multiple sclerosis". Cells 14.18 (2025): 1408.
10. Garton T., et al. "Neurodegeneration and demyelination in multiple sclerosis". Neuron 112.19 (2024): 3231-3251.
11. Grosu C., et al. "The role of nutrition and physical activity in modulating disease progression and quality of life in multiple sclerosis". Nutrients 17.16 (2025): 2713.
12. Hajeer S., et al. "Association between vitamin D deficiency and multiple sclerosis- MRI significance: A scoping review". Heliyon 9.5 (2023): e15754.
13. Jason LA and Bobak T. "Using systems theory to improve intervention outcomes". Professional Psychology Research and Practice 53.4 (2022): 415-422.
14. Javanbakht P., et al. "Quercetin as a possible complementary therapy in multiple sclerosis: Anti-oxidative, anti-inflammatory, and remyelination potential properties". Heliyon 9.11 (2023): e21741.
15. Mavaddatiyan L, Khezri S and Froushani SMA. "Molecular effects of curcumin on the experimental autoimmune encephalomyelitis". Veterinary Research Forum (2021).
16. Nemati MH., et al. "Microbiota-Driven Mechanisms in Multiple sclerosis: pathogenesis, therapeutic strategies, and biomarker potential". Biology 14.4 (2025): 435.
17. Nguyen KHH., et al. "Human immune system: Exploring diversity across individuals and populations". Heliyon 11.2 (2025): e41836.
18. Puri V., et al. "A Comprehensive review on Nutraceuticals: therapy support and formulation challenges". Nutrients 14.21 (2022): 4637.
19. Qin P, Sun Y and Li L. "Mitochondrial dysfunction in chronic neuroinflammatory diseases (Review)". International Journal of Molecular Medicine 53.5 (2024).
20. Rajabi M., et al. "Primary Progressive multiple sclerosis: new therapeutic approaches". Neuropsychopharmacology Reports 45.3 (2025): e70039.
21. Sadee W., et al. "Pharmacogenomics: Driving Personalized Medicine". Pharmacological Reviews 75.4 (2023): 789-814.
22. Shi M., et al. "Multiple sclerosis: An overview of epidemiology, risk factors, and serological biomarkers". Acta Neurologica Scandinavica 2024.1 (2024).
23. Shirol S, Subramaniam K and Ziemssen T. "A review of the impact of platform therapies (DMTs) on associated clinical symptoms of multiple sclerosis". Journal of Multidisciplinary Healthcare 18 (2025): 6939-6954.

24. Stoiloudis P., et al. "The Role of Diet and Interventions on Multiple Sclerosis: A Review". Nutrients 14.6 (2022): 1150.
25. Thomas OG, Rickinson A and Palendira U. "Epstein-Barr virus and multiple sclerosis: moving from questions of association to questions of mechanism". Clinical & Translational Immunology 12.5 (2023): e1451.
26. Wan Y., et al. "Current advances and future trends of hormesis in disease". NPJ Aging 10.1 (2024): 26.
27. Yusri K., et al. "The role of NAD+ metabolism and its modulation of mitochondria in aging and disease". NPJ Metabolic Health and Disease 3.1 (2025): 26.
28. Zaigham SB and Paeng D. "Effects of Mucuna pruriens (L.) DC. and Levodopa in Improving Parkinson's Disease in Rotenone Intoxicated Mice". Current Issues in Molecular Biology 46.8 (2024): 9234-9244.